Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Talabostat by BioXcel Therapeutics for Solid Tumor: Likelihood of Approval
Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Talabostat by BioXcel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Talabostat by BioXcel Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Talabostat by BioXcel Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Talabostat by BioXcel Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...